Results 181 to 190 of about 7,426,653 (346)

The health of Australia's males: from birth to young adulthood (0-24 years) [PDF]

open access: yes
SummaryThe years from birth to young adulthood (ages 0-24) encompass a breadth of life stages in which males undergo major developmental changes and acquire important social and health behaviours. In 2011, 3.7 million males (more than one-third of the

core  

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

open access: yesMolecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li   +10 more
wiley   +1 more source

Motor unit number and transmission stability in octogenarian world class athletes: Can age-related deficits be outrun? [PDF]

open access: bronze, 2016
Geoffrey A. Power   +7 more
openalex   +1 more source

Step width variability as a discriminator of age-related gait changes [PDF]

open access: gold, 2020
Ανδρέας Σκιαδόπουλος   +4 more
openalex   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

open access: yesMolecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff   +11 more
wiley   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Cohort differences in cognitive aging and terminal decline in the Seattle Longitudinal Study.

open access: green, 2011
Denis Gerstorf   +4 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy